Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment – technical preparation, effectivity and clinical findings

Giuseppe Di Bella 1, Luciano Gualano 2, Luigi Di Bella +

1 Di Bella Foundation, Via Guglielmo Marconi 51 Bologna, 40122 Italy
2 Private Laboratory of Physiology, Via Stefano Giovanni Marianini, Modena 41123, Italy

Correspondence to: Dr. Giuseppe Di Bella
Via Marconi 51 “Di Bella Foundation”
Post code 40122, Bologna, Italy.
TEL: +39 051 239662; FAX: +39 051 230369; E-MAIL: posta@giuseppedibella.it

Submitted: 2017-09-05   Accepted: 2017-11-23   Published online: 2017-12-22

Key words: melatonin; adenosine; glycine; hydrogen bond; apoptosis; Di Bella Method

Abstract
Melatonin has shown the potential to inhibit growth of different tumors, both in vitro and in vivo. There is clear evidence that the administration of melatonin alone or in combination with chemo and radiotherapy in cancer patients with advanced solid tumors has been associated with improved outcomes of tumor regression and survival. Moreover, chemotherapy has been shown to be better tolerated in patients treated with melatonin. However, there are different ways of preparation and administration of melatonin to the patient. This review article aims to offer the insight into the preparation, biological features and clinical findings in its use in cancer patients.

Melatonin (MLT) can only be solubilized in water at 40–45 °C; at other temperatures it can only be solubilized in alcohol. It is absorbed in the human body complexed with adenosine by a hydrogen bond. It acts on two common denominators: proliferation and differentiation; in addition to anticancer homeostasis, MLT has a documented antidegenerative and immunomodulatory role. It also plays an important role in limiting oxidative stress, affecting blood and bone marrow constituent ratio, leukocyte formula regulation, hemoglobin synthesis, platelet genesis, aggregation and in erythrocyte resistance. Despite of all these important roles, most well-known features are probably the least important ones, such as sleep and wakefulness regulation and its effect on jet lag.

In the preparation formulated by Prof. Di Bella, melatonin with adenosine at a ratio of 1:4, stabilized with 30% of glycine (MLT-DBM), has been used since 1994 in many patients with various indications and positive therapeutic responses and a total absence of toxicity. This method can be a good alternative to commercially produced preparations, as it was scientifically proved and published worldwide at conferences and in various medical journals.

To cite this article: Neuroendocrinol Lett 2017; 38(7):465–474
Abbreviations:

AMP - Adenosine Monophosphate
APUD - Uptake and Decarboxylation
AR - Androgen Receptor
ATRA - All Trans Retinoic Acid
CASPASE - Protease Enzyme
CX 32 - Gap junction protein gene
DBM - Di Bella Method
DNES - Diffuse NeuroEndocrine System
EGF - Epidermal Growth Factor
EGFR - Epidermal Growth Factor Receptor
ER - Estrogen Receptor
FGF - Fibroblastic Growth Factor
GF - Growth Factor
GH - Growth Hormone
GHR - Growth Hormone Receptor
GMP - Guanosine Monophosphate
S-HT - Serotonin
HIOMT - Hydroxyindole-O-methyltransferase
IFN - Interferon
IL - Interleukin
MLT - Melatonin
MT1,MT2 - Melatonin Receptors
NAT - N-acetyltransferase
NGF - Nerve Growth Factor
PKA - Protein Kinase A
RAR,ROR,RXR,RZR - Retinoid Receptors
RAS - Rat Sarcoma Protein
SST - Somatostatin
SSTR - Somatostatin Receptor
TGF - Transforming Growth Factor
VEGF - Vascular Endothelial Growth Factor
WV - Weight, Volume

INTRODUCTION

Melatonin with adenosine at a ratio of 1:4, stabilized with around 30% of glycine, has been used since 1994 in the DBM, in pharmaceutical freeze-dried form. In the pharmaceutical preparation according to the Di Bella method, melatonin is conjugated to adenosine by freeze-drying, in order to ensure greater bioavailability of the medication. Melatonin is able to form a complex with adenosine, probably the π type, due to orbital overlap of the aromatic systems and of the electronic double bonds of the nitrogen atoms. The complex is then stabilized by glycine, which, because of the fairly low pKa, contributes to the formation of hydrogen bridges. The formation of the complex involves a considerable variation with respect to the characteristics of the individual components: the complex is fully soluble in water, at concentrations at which adenosine and melatonin alone would precipitate or would not even dissolve.

PRODUCTION AND ADMINISTRATION OF THE MLT

Although it is still a galenic preparation, the method of production is regulated to ensure maximum product quality. Good preparation standards are applied to the processing stages and the end product is analyzed by qualitative and quantitative determination of the active ingredients.

The freeze-drying of the water solution of melatonin-adenosine-glycine is regulated by a set-up method. The freeze-dried form is extremely hydrosoluble and can be prepared in vial form for oral use, intramuscular or intravenous injection. Freeze-drying process effectively dehydrates various substances, in a way that the end product retains its particular characteristics and subsequently sterile distilled water for injectable preparations is added, to restore the specific properties of the original solution. The freeze-dried product can also be used in oral vials, in which the water is added at the time of administration.

Melatonin itself is very difficult to dissolve in water, with satisfactory solubility only at 40–45°C. After lengthy testing, adenosine was found to be the most suitable molecule to easily dissolve melatonin in water. In particular, the ideal ratio was found to be four moles of adenosine (267.24 g) to one mole of melatonin (232.28 g).
The preparation of melatonin with a high degree of purity consists of the following steps:

a. reacting potassium phthalimide with dibromopropane to obtain 3-bromopropilphthalimide;
b. reacting 3-bromopropilphthalimide with sodium acetate in to obtain ethyl-2-acetyl phthalimidopentanoate;
c. reacting ethyl 2-acetyl phthalimidopentanoate with diazop-anisidine to obtain 2-carboxyethyl-3-(2-phthalimidoethyl)-5-methoxy-indole;
d. reacting 2-carboxyethyl-3-(2phthalimidoethyl)-5-methoxy-indole with sodium hydroxide and then with sulphuric acid to obtain impure 5-methoxytriptamine;
e. reacting impure 5-methoxytriptamine with hexamethylene-disilazane and the silyl substitution product is extracted with methylene dichloride. After refluxing for 12/14 hours, the impure 5-methoxytriptamine is extracted with methylene dichloride and acetone. After refluxing for 12/14 hours, the impure 5-methoxytriptamine is treated with hexamethylene disilazane, to obtain mono and di-silyl substitution products, then the solution is distilled under normal pressure so as to recover excess hexamethylene-lsilazane and the silyl substitution products are hydrolyzed with aqueous methanol in order to obtain essentially pure 5 methoxytriptamine (Di Bella L et al. 1997).

Glycine in the vials is present both as a freeze-drying co-adjuvant and as an agent making the pharmaceutical form isotonic; as it is not conveyed by intestinal adenosine, being bound to exogenous adenosine with a hydrogen bond is even more important for injectable melatonin. The vials must respect the technology for sterile-apyrogenic preparations. Parenteral route is usually preferred when difficulties with the absorption of melatonin by the digestive tract or inability of its ingestion are present and when it is necessary to administer high doses. Just before use, vials of freeze-dried MLT should be diluted in 10 ml of distilled sterile water for injectable preparations. It is not necessary to use saline solution as the presence of glycine makes it isotonic. The quantity obtained can be injected in a single administration, but very slowly because adenosine is a vasodilator and could lead to a drop in blood pressure. It is therefore advisable to test the patient's reactivity by using 1 ml of solution. The solution can be injected intramuscularly or intravenously.

**BIOLOGICAL FEATURES OF MLT AND ITS ANTICANCER ACTIVITY**

Numerous studies have described the in vitro effects of MLT on the proliferation of tumor cell lines and on their apoptosis. The dynamics involved in the division of normal cells and tumor cells depend on and are coordinated by a hierarchy of circadian timekeepers. The bio-activities of MLT are either available or not in vivo in a coordinated way, in specific circadian phases (Bartsch et al. 1997, 1999). The authors conclude that the numerous data on the influence of MLT on tumor biology in vitro indicate that the circadian state of administration of MLT to cancer patients also determines its anticancer activity. It has been demonstrated that MLT has a dose-dependent, antioxidant and experimentally reproducible effect, with significant implications in the prevention and treatment of tumors for the protection of nuclear and mitochondrial DNA from the potentially neoplastic oxidative stress (Kojima et al. 1997; Reiter et al. 2000).

The ability of MLT to protect DNA from damage caused by carcinogenic chemical substances is also a decisive factor. These concepts were applied in clinical practice by Prof. Di Bella, wherein the biochemistry of MLT or of the other pineal indoles, the presence of taurin and of many peptides, the innervation or the functional circadian or seasonal cycles, or the correlation with the hypophysis or other endocrine glands or releasing factors can fully clarify the antiblastic mechanisms of MLT action. In these reactions, which lead to the production of both NO and polyamines, MLT can play a fundamental role. In the book “Cancro, siamo sulla strada giusta” (Di Bella L 1998), Prof. Di Bella put forward a new interpretation of this complex problem, the ability of MLT to interact with the tumor biology, in relation to the central dogma of biology. According to the current concepts of molecular biology, a fundamental role is played by the preexistence of information for every amino acid sequence, the element of protein synthesis forming the basis for physiological and neoplastic life in its essential expressions of morpho-functional proliferation and differentiation. Di Bella, in fact, identified a primary role of MLT in the ubiquitous arrangement of the phosphoric esters of AMP, ADP, and ATP. This concept is shared by the school of thought headed by Goldberger (Blasi et al. 1971; Meyers et al. 1975), who also admits the possibility of self-assembly, and that the protein can spontaneously re-acquire its three-dimensional structure with full biological activity. It could be the same or another
protein which influences the intermolecular reactions. Some proteins act as molecular chaperones and by hydrolyzing ATP activate the deployment of inert protein structures without this reaction. The mechanism of action was explained by Ellis (1996), who defined the chaperonins as sequestrants containing the individual protein structures folded in the Anfinsen Cage. According to Prof. Di Bella, in tumor biology the action of the chaperonins takes place mainly through the hydrolysis of ATP, ADP, and AMP, their binding with adenosine, or in their hydrogen bond with MLT. In the last decade, the attention of many researchers was focused on MLT, formerly considered merely an epiphyseal secretion, while it is now believed to be a component of the Diffuse Neuro-Endocrine System (DNES), also known as Amine Precursor Uptake and Decarboxylation (APUD) present in many more or less ubiquitous cellular aggregates, also able to produce MLT (Kvetnoy et al. 1986).

Platelets can be considered omnipresent, multifactorial and itinerant elements of a changeable and ubiquitous APUD system. Platelets sometimes behave like a melatonergic and dopaminergic, serotonergic and adrenergic neuron, according to the various local conditions and attracting nature of the nuclei. Platelets can absorb and store 5-HT; they can also synthesize MLT since they too are provided with 5-HT-decarboxylase. A large amount of pharmacological data demonstrated considerable functional affinity between the platelets and neurons of the serotonergic system. This function of the platelets, which release their stores of 5-HT and expel material from their granules when they are activated by appropriate signals, was considered very similar to the release of neurotransmitters by the central neurons. The release of biologically active molecules by the platelets is similar to that of the serotonergic and adrenergic central neurons (Kvetnoy et al. 1986; Di Bella L 1998).

Variable concentrations of MLT have been found in the following locations: retina, Harder glands (tear glands), intestinal mucosa, cerebellum, epithelium of the airways, liver, kidneys, adrenal glands, thymus, thyroid, pancreas, ovaries, testicles, carotid sinus, placenta, endometrium, mast cells, natural killer cells, leukocytes, eosinophils, endothelial cells and also in platelets and megakaryocytes, as shown by the research carried out by Prof. Di Bella on the platelet-megakaryocyte-MLT interaction. This generalized diffusion shows that MLT has a unique role among the components of the DNES/APUD system and is an essential component of the response and control of the body’s
anticancer protection system, acting on all organs. MLT can be considered extrapineal, as a key molecule of the paracrine system for the local coordination of the intercellular reactions, an irreplaceable element in the prevention and treatment of tumors. The fact that many cells adjacent or close to the production sites of MLT have membrane receptors for MLT confirms the above findings. Kvetnoy et al. have studied and experimentally confirmed the direct participation and active role of MLT and DNES/APUD hormones on the etiopathogenesis and proliferation of tumors and on antineoplastic therapy (Kvetnoy et al. 1994, 1997, 2002). An analysis of the physiological characteristics of many biologically active substances produced by the cells of the DNES/APUD system, such as melatonin, serotonin, gastrin, insulin, glucagon, somatostatin, etc., suggests an important function of these cells and hormones in tumor growth. A study of the role and significance of the DNES/APUD system, and above all of the melatonin-secreting extrapineal cells, in tumor pathogenesis provides a new interpretation of the endogenous mechanisms of the responses induced by tumors in various organs and tissues. Hyperplasia of the enterochromaffin cells that produce MLT, of the BETA pancreatic insulin secreting cells, of the somatostatin-producing D cells, and of the noepinephrine-producing adrenal NEP cells has been documented in the tumor onset and proliferation stages, while there is a significant decrease in the number of these cells in the more advanced or terminal stages of cancer. The experimental studies by Zabezhinskii et al. (1999) have shown the same behavior of these cellular aggregates in Lewis lung carcinoma in mice. Early-stage circumscribed tumors, with a modest degree of proliferation, only slightly differenti-

![Diagram](image-url)

**Fig. 4.** 1) Melatonin negatively regulates phospholipase C and the second messengers IP3 and DAG. 2) Melatonin also activates the intrinsic mitochondrial pathway that leads to activation CASPASE 8 thus inducing apoptosis. 3) Melatonin is responsible for activation of a cytostatic pathway when in contact with the cytosolic protein Calmodulin; the MLT-Calmodulin bond reduces the levels of cytosolic Ca2+ and closes, at the level of the plasma membrane, the Ca2+ channels at their entry point. 4) At the level of the nuclear membrane, melatonin interacts with RZR (orphan) and ROR receptors, which can also be activated by the retinoids. The receptors RAR and RXR of the retinoids and VDR of vitamin D, ROR and RZR dimerize and thus activate, in an amplified way, the nuclear transcription factors through methylation reactions, silencing the sequences of the mutation genes with a cytostatic side effect. 5) The hydroxylolization of Melatonin, increasing its bioavailability and ubiquitous diffusion, facilitates and reinforces the ability to bind the nuclear receptors RZR, ROR, transmembrane receptors (MT1 and MT2) with 7 transmembrane domains associated with G proteins which activate multiple signaling lines: – The bond with the MT1 receptor inhibits adenylate cyclase and consequently the second messenger (cAMP) and the reactions of phosphorylation of the protein PKA; – The bond with the MT2 receptor inhibits guanylate cyclase and the formation of GTP, and of the protein RAS (Di Bella G et al. 2013).
Angiogenic Factors:
- FGF
- IGF1
- HGF
- Interl. 8

EvN
e-NOS
VEGF
CM
TGF
PGE2
VIP
PDGF

MDB Molecules: Angiogenesis Inhibitors
- Somatostatin
- Vitamin D3, E, C
- Melatonin
- Bromocriptine
- Condroitin Sulphate
- Carbegolin
- Calcium
- Retinoids
- Glucosamine

Fig. 5. The hydrosolubilization of Melatonin, increasing its bioavailability and ubiquitous diffusion, facilitates and reinforces the ability to bind the nuclear receptors RZR, ROR, transmembrane receptors (MT1 and MT2) with 7 transmembrane domains associated with G proteins which activate multiple signaling lines: – The bond with the MT1 receptor inhibits adenylate cyclase and consequently the second messenger (cAMP) and the reactions of phosphorylation of the protein PKA; – The bond with the MT2 receptor inhibits guanylate cyclase and the formation of GTP and of the protein RAS.

Ated, not metastized, show less activity, demonstrated by the morpho-functional aspects and by hypoplasia of the intestinal enterochromaffin cells, including the histamine-producing ECL cells, the G cells of the stomach which produce gastrin, the pancreatic A cells, which secrete glucagon, the adrenal EP cells which secrete epinephrine. All these cell aggregates increase considerably both in number and activity as tumor proliferation, and invasion proceeds, reaching an evident degree of hypertrophy in the more advanced or terminal stages. In experimental studies on male Wistar rats with sarcoma-45, a significantly greater concentration of MLT was observed (seen by the bonding of its radiomarked isotopes 3H-MLT and 125 Iodo-MLT), with an evident homeostatic function of limiting tumor expansion in many vital organs such as the intestine, liver, respiratory epithelium, kidneys adrenal glands and pancreas. The absence of an increase in the melatonin concentration in these organs in healthy animals confirms that MLT is an anticancer homeostatic mechanism (Mediavilla et al. 1997; Di Bella L et al. 2015).

Melatonin use in cancer patients have started in 1974, when melatonin prepared according to Prof. Di Bella’s formulation, in 25 mg bottles, at high doses of a thousand milligrams per day for 11 days was administered to the patient. At the request of the patient and family members with informed consent, and with the consent of the hospital management and the relative consultant, in view of the lack of therapeutic alternatives, a forty-year old patient, admitted to the general medical ward at the Maggiore-Pizzardi Hospital in Bologna, with chemo and radiotherapy-resistant lymphosarcoma after repeated cycles of chemo and radiotherapy, with bilateral laterocervical, axillary lymph node mediastinic, bilateral inguinal and splenic progression, was very slowly (over approx. 8 hours) and intravenously administered 1000 mg of melatonin for 11 days. During the course of each day, the patient was intravenously administered 4 saline drips of 500 ml, each containing ten 25 mg bottles of freeze-dried melatonin, lasting 2 hours, totaling 1000 mg per day. No other drug of any kind was administered in order to ascertain the effect
of the MLT without interference. A complete and stable objective response was observed and radiographically documented, recorded in the patient’s medical notes. The patient passed away due to acute meningitis 15 years later. It was not possible to administer similar doses in other cases because the supplier (IFLO, Milan) stopped its production and because of the lack of hospital ward cooperation. Lymphoproliferative diseases are particularly sensitive to the action of DBM melatonin, as we have seen in many other published cases. The rapidity of the response in the case described above, the total absence of toxicity and the stability of the result suggest that significant progress in cancer treatment could be achieved, with particular efficacy in lymphoproliferative forms, as confirmed not only by this single case but also by the numerous reported cases of oral administration of the DBM (Di Bella & Fraschini 1997; Todisco et al. 2001, 2009; Di Bella G et al. 2012).

DISCUSSION AND CONCLUSIONS

The positive anticancer effect in terms of objective response, survival rates, performance status, tolerability and the absence of significant toxicity has been ascertained in thousands of patients, reported at national, European and international conferences, and published in around thirty scientific papers, documenting around eighty cases of a variety of types of tumor: sarcomas (Di Bella G et al. 2016), glioblastomas (Di Bella G et al. 2015), breast cancer (Di Bella G 2008, 2011; Di Bella G et al. 2013), prostate cancer (Di Bella G et al. 2013), neuroblastomas (Di Bella G et al. 2009), esophageal cancer (Di Bella G et al. 2009), non-small cell lung cancer (Norsa et al. 2006), cervicofacial tumors (Di Bella G et al. 2012), lymphoproliferative diseases (Todisco et al. 2001, 2009; Di Bella G et al. 2012).

Prof Luigi Di Bella defined the integration of MLT in his method containing immunomodulating, trophic, differentiating, and antiproliferative molecules, saying that any medical treatment not including Melatonin was unable to completely cure and stabilize a tumor, and that it represents a necessary condition albeit not sufficient. He summarized his therapeutic reasoning and biological method as: “being more essential than the impracticable and imaginary killing of all the tumoral elements, the achievement of all the conditions known, possible and not dangerous within certain limits, capable of hindering their development, as far as death also by apoptosis, especially through the interplay between numerous growth factors. The essential lies in activating all the inhibitors of the known growth factors at the right doses and at the right time. The DBM protocol was created in this setting, the setting of life, not that of intoxication and cell death, a method that supports or enhances vital reactions, without using statistical precision to find the most appropriate doses

Fig. 6. Melatonin is able to inhibit the release of fatty acids from adipose tissues and the absorption of fatty acids by tumors.
to kill. A tumor is a deviation from normal life, so the reactions that have deviated must be returned to their normal status by enhancing those means that physiology considers to be essential for normal life; and "there is, nor ever will there be, no cytotoxic chemotherapy (nor monotherapy) that can cure a solid tumor, only a method, a rational and biological multitherapy, a complex of synergic and factorially interactive substances, each with its own individual atoxic anticancer activity and sequentially or simultaneously acting centripetally together on the myriad of biological reactions involved in the tumoral life, leading gradually to normality of the vital reactions deviated by the tumor." (Di Bella & Rossi 1979; Di Bella L et al. 1980; Di Bella L 1997; Di Bella L & Gualano 2006; Di Bella G et al. 2013).

A review of the literature confirms the considerable functional versatility of MLT, which can in fact have both a direct and indirect anticancer effect, working in synergy with other differentiating, antiproliferative, immunomodulating and trophic molecules of the anticancer treatment formulated by Luigi Di Bella (Di Bella Method, DBM: Somatostatin, Retinoids solubilized in vitamin E, Ascorbic Acid, Vitamin D3, Pro-lactin inhibitors, Chondroitin sulfate). The interaction of MLT with the DBM molecules counters the multiple processes that characterize the tumor phenotype (induction, promotion, progression and/or dissemination, tumoral mutation). All these features suggest the use of these molecules in oncological diseases may be recommended.

REFERENCES


